Sanofi makes $470M move for Vig­il's Alzheimer's drug, while an­oth­er as­set re­turns to Am­gen

Sanofi plans to buy Vig­il Neu­ro­science, a drug­mak­er ad­vanc­ing TREM2 ag­o­nism pro­grams that de­rive from Am­gen.

The French phar­ma will ac­quire Vig­il for its oral …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER